PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK) announced that four abstracts highlighting results from its
Research and Development programs will be presented at the 99th annual
meeting of the American Association for Cancer Research (AACR) in San
Diego.
Details of the presentations are as follows:
-- Identification and Characterization of Novel Tyrosine Kinase Inhibitors
Targeting Vascular Endothelial Growth Factor Receptor 2; Sunday, April
13, 2008, 1:00 - 5:00pm; Experimental and Molecular Therapeutics 10;
Abstract # 1439
-- Mechanism of Induction of Apoptosis by TLK199 (Telintra(R)) in Human
Leukemia Cell Lines; Monday, April 14, 2008, 8:00am - 12noon;
Experimental and Molecular Therapeutics 10; Abstract # 2270
-- Identification of a Novel Class of Nonpeptidyl Small-Molecule
Inhibitors of the Human Proteasome; Monday, April 14, 2008,
1:00 - 5:00pm; Experimental and Molecular Therapeutics 28;
Abstract # 3271
-- Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug
Discovery at Telik; Tuesday, April 15, 2008; 1:00 - 5:00pm; Cancer
Chemistry 11; Abstract # 4754
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on
discovering, developing and commercializing novel small molecule drugs to
treat serious diseases. The company's most advanced investigational drug
candidates in clinical development are TELINTRA, a modified glutathione
analog for the treatment of cytopenias due to myelodysplastic syndrome or
chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment
of advanced ovarian cancer and non-small cell lung cancer
'/>"/>
| SOURCE Telik, Inc. Copyright©2008 PR Newswire. All rights reserved |